Alnylam Pharmaceuticals (ALNY) is out with 5X15 pipeline goals.
The company says it now plans to have "six to seven genetic medicine programs in the clinic, including at least two programs in Phase 3 and five to six programs that will have achieved human proof-of-concept results supporting further development," by the end of 2015.
2014 expectations: Enrollment in APOLLO (patisiran) and collection of "key clinical endpoint data" from Phase 2 extension study with results due late in the year; initiation of ALNY's second Phase 3 study (ALN-TTRsc in the cardiac amyloidosis) and data from a Phase 2 trial of ALN-TTRsc by year end; ALN-AT3 (hemophilia) set to start Phase 1.
FY13 year end cash guidance: $350M. (PR)